These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 30548091)

  • 1. Concurrent chemoradiotherapy by simultaneously integrated boost volumetric-modulated arc therapy for nasopharyngeal carcinoma-toxicity/quality of life and survival.
    Fang FM; Huang TL; Lin YH; Chien CY; Chuang HC; Luo SD; Lin HC; Lin YT; Li SH; Liao KC; Tsai WL
    Head Neck; 2019 May; 41(5):1282-1289. PubMed ID: 30548091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction chemotherapy plus concurrent chemoradiotherapy versus induction chemotherapy plus volumetric modulated arc therapy alone in the treatment of stage II-IVB nasopharyngeal carcinoma patients: a retrospective controlled study.
    Liu L; Fei Z; Chen M; Zhao L; Su H; Gu D; Lin B; Cai X; Lu L; Gao M; Ye X; Jin X; Xie C
    Radiat Oncol; 2018 Aug; 13(1):148. PubMed ID: 30103765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quality of life and survival outcome for patients with nasopharyngeal carcinoma treated by volumetric-modulated arc therapy versus intensity-modulated radiotherapy.
    Huang TL; Tsai MH; Chuang HC; Chien CY; Lin YT; Tsai WL; Fang FM
    Radiat Oncol; 2020 Apr; 15(1):84. PubMed ID: 32307024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Final results of a randomized phase III trial of induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in patients with stage IVA and IVB nasopharyngeal carcinoma-Taiwan Cooperative Oncology Group (TCOG) 1303 Study.
    Hong RL; Hsiao CF; Ting LL; Ko JY; Wang CW; Chang JTC; Lou PJ; Wang HM; Tsai MH; Lai SC; Liu TW
    Ann Oncol; 2018 Sep; 29(9):1972-1979. PubMed ID: 30016391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus neoadjuvant chemotherapy plus concurrent chemoradiotherapy for ascending or descending types of nasopharyngeal carcinoma: A retrospective study.
    Lin Q; Lu L; Wang X; Lin Y; Chen Y; Chen H; Chen S; Lin S; Zhang Y; Zheng P; Chen X
    Am J Otolaryngol; 2022; 43(1):103193. PubMed ID: 34509080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival benefit of induction chemotherapy for locally advanced nasopharyngeal carcinoma: prognosis based on a new risk estimation model.
    Liu W; Yu B; Luo Y; Li J; Yuan X; Wu S; Liang B; Lv Z; Li Y; Peng X; Lu J; Peng X; Liu X
    BMC Cancer; 2021 May; 21(1):639. PubMed ID: 34051750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment outcomes and late toxicities of 869 patients with nasopharyngeal carcinoma treated with definitive intensity modulated radiation therapy: new insight into the value of total dose of cisplatin and radiation boost.
    Ou X; Zhou X; Shi Q; Xing X; Yang Y; Xu T; Shen C; Wang X; He X; Kong L; Ying H; Hu C
    Oncotarget; 2015 Nov; 6(35):38381-97. PubMed ID: 26485757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcomes of concurrent chemoradiotherapy with volumetric modulated arc therapy in patients with locally advanced nasopharyngeal carcinoma.
    Imano N; Murakami Y; Nakashima T; Takeuchi Y; Takahashi I; Doi Y; Nishibuchi I; Kimura T; Wadasaki K; Ueda T; Hirakawa K; Nagata Y
    Jpn J Radiol; 2017 Nov; 35(11):673-680. PubMed ID: 28887732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival of stage II nasopharyngeal carcinoma patients with or without concurrent chemotherapy: A propensity score matching study.
    Liu DH; Zhou XY; Pan YG; Chen S; Ye ZH; Chen GD
    Cancer Med; 2020 Feb; 9(4):1287-1297. PubMed ID: 31859464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy for the treatment of locoregionally advanced nasopharyngeal carcinoma: a retrospective controlled study.
    Qiu WZ; Huang PY; Shi JL; Xia HQ; Zhao C; Cao KJ
    Chin J Cancer; 2016 Jan; 35():2. PubMed ID: 26739148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Volumetric modulated arctherapy for locally advanced nasopharyngeal carcinoma: Clinical efficacy and late toxicity.
    Hommadi M; N'da G; Bertrand C; Randriamaroson N; Benlemlih M; Mosse WBA; El Mejjaoui S; Kebdani T; El Kacemi H; Benjaafar N
    Cancer Radiother; 2022 May; 26(3):433-439. PubMed ID: 34366239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy of induction chemotherapy in the treatment of stage II nasopharyngeal carcinoma in intensity modulated radiotherapy era.
    Li PJ; Mo HY; Luo DH; Hu WH; Jin T
    Oral Oncol; 2018 Oct; 85():95-100. PubMed ID: 30220326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lobaplatin-based concurrent chemoradiotherapy in elderly nasopharyngeal carcinoma.
    Yu YF; Zhou P; Zhou R; Lin Q; Wu SG
    Ann Med; 2024 Dec; 56(1):2383959. PubMed ID: 39086168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ten-year outcomes of survival and toxicity for a phase III randomised trial of concurrent chemoradiotherapy versus radiotherapy alone in stage II nasopharyngeal carcinoma.
    Li XY; Chen QY; Sun XS; Liu SL; Yan JJ; Guo SS; Liu LT; Xie HJ; Tang QN; Liang YJ; Wen YF; Guo L; Mo HY; Chen MY; Sun Y; Ma J; Tang LQ; Mai HQ
    Eur J Cancer; 2019 Mar; 110():24-31. PubMed ID: 30739837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Home enteral nutrition may prevent myelosuppression of patients with nasopharyngeal carcinoma treated by concurrent chemoradiotherapy.
    Li X; Zhou J; Chu C; You Q; Zhong R; Rao Z; Hu W
    Head Neck; 2019 Oct; 41(10):3525-3534. PubMed ID: 31301097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of sequential chemoradiotherapy in stage II and low-risk stage III-IV nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy: A propensity score-matched analysis.
    Xu C; Sun R; Tang LL; Chen L; Li WF; Mao YP; Zhou GQ; Guo R; Lin AH; Sun Y; Ma J; Hu WH
    Oral Oncol; 2018 Mar; 78():37-45. PubMed ID: 29496056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term outcomes of concurrent chemoradiotherapy versus radiotherapy alone in stage II nasopharyngeal carcinoma treated with IMRT: a retrospective study.
    Su Z; Mao YP; Tang J; Lan XW; OuYang PY; Xie FY
    Tumour Biol; 2016 Apr; 37(4):4429-38. PubMed ID: 26499947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the efficacy between concurrent chemoradiotherapy with or without adjuvant chemotherapy for stage II nasopharyngeal carcinoma.
    Chen J; Liu T; Sun Q; Jin T
    Medicine (Baltimore); 2020 Jul; 99(29):e20443. PubMed ID: 32702809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Role of Neoadjuvant Chemotherapy in the Treatment of Nasopharyngeal Carcinoma: A Multi-institutional Retrospective Study (KROG 11-06) Using Propensity Score Matching Analysis.
    Song JH; Wu HG; Keam BS; Hah JH; Ahn YC; Oh D; Noh JM; Park HJ; Lee CG; Keum KC; Cha J; Cho KH; Moon SH; Kim JY; Chung WK; Oh YT; Kim WT; Cho MJ; Kay CS; Kim YS
    Cancer Res Treat; 2016 Jul; 48(3):917-27. PubMed ID: 26727716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of advanced nasopharyngeal cancer using low- or high-dose concurrent chemoradiotherapy with intensity-modulated radiotherapy: A propensity score-matched, nationwide, population-based cohort study.
    Chen TM; Lin KC; Yuan KS; Chang CL; Chow JM; Wu SY
    Radiother Oncol; 2018 Oct; 129(1):23-29. PubMed ID: 29277447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.